Murali Ramachandra, Aurigene Oncology CEO

Dr. Red­dy's sub­sidiary hits the pause but­ton on drug de­vel­op­ment for pso­ri­a­sis

A biotech sub­sidiary of the In­dia-based phar­ma com­pa­ny Dr. Red­dy’s Lab­o­ra­to­ries is halt­ing the de­vel­op­ment of a pso­ri­a­sis drug.

In an an­nounce­ment to the Na­tion­al Stock Ex­change of In­dia on Fri­day, the biotech Au­ri­gene On­col­o­gy post­ed the re­sults of its Phase II study of the oral can­di­date AUR101 in pa­tients with mod­er­ate to se­vere plaque pso­ri­a­sis.

The 128-per­son study, dubbed In­dus-3, was re­port­ed to meet its pri­ma­ry re­spon­si­bil­i­ty of a pso­ri­a­sis area and sever­i­ty in­dex (PASI) re­sponse at 12 weeks at the 400 mg BID dose, against the place­bo. How­ev­er, the pri­ma­ry end­point of a PASI at 12 weeks for the 200 mg BID and 400 mg QD dosage forms was not met. As a re­sult, Au­ri­gene stat­ed that it will close the clin­i­cal de­vel­op­ment of AUR101 in pa­tients with pso­ri­a­sis.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.